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The purpose of this research was to investigation the morphological features of human placenta 
with karyotyped trisomy 21, 18 and 13 chromosomes. The study included 50 placenta of fetuses 
in miscarriages pregnancy at 19–20 weeks, among them 10 placentas obtained as a result of 
induced abortions due to karyotyped trisomy 21 of the fetuses; 10 placentas obtained as a result 
of induced abortions due to karyotyped trisomy 18 of the fetuses; 10 placentas obtained as a 
result of induced abortions due to karyotyped trisomy 13 in the fetuses; 20 placentas obtained as 
a result of spontaneous miscarriages without any congenital defects and abnormal karyotype of 
the fetuses. As a result of the investigation, in placentas with karyotyped trisomies, a violation of 
villi branching was noted. With karyotyped trisomy 21, inhibition of angiogenesis and sclerosis 
of villi with proliferation of fibroblasts were revealed. In cells of chorionic villi with karyotyped 
trisomy 18, increased apoptosis was noted. In placentas with karyotyped trisomy 13 hydropic 
changes in villus stroma and inhibition of angiogenesis were noted.
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Introduction
Proper placental development and function are central to the health of both the 
mother and the fetus during pregnancy. A critical component of healthy placental func-
tion is the proper development of its vascular network [1]. The process of angiogenesis — 
the formation of new blood vessels from preexisting ones — is a hallmark of tissue repair, 
expansion, and remodeling in physiological processes, such as wound healing, ovulation, 
and embryo development, and in various pathologies including cancer, atherosclerosis, 
and chronic inflammation. Therefore, different in vivo, ex vivo, and in vitro bioassays and 
techniques have been developed to investigate the specific stages of the angiogenesis [2]. 
According to the literature, placental ultrasound in cases of trisomy 21  shows fe-
tal vascular malperfusion and impaired differentiation of the villous chorion [3]. At the 
same time, the volume of the placenta with trisomy 21 does not significantly differ from 
the volume of the placenta of fetuses with a normal karyotype [4]. In addition, trisomy 
21 shows a tendency to form an absolutely short umbilical cord [3]. In placentas with tri-
somy 18 and 13 a decrease in the vascularization index and blood flow was revealed [5].
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The frequency of aneuploidy including miscarriages for medical reasons, stillbirths and 
newborns is: trisomy 21 — 35.6 per 10,000 births, trisomy 18 — 4.08 per 10,000 births, 
trisomy 13  — 1.68  per 10,000  births [6–8]. In addition, according to J. M. Jackson et al. 
(2014) the rate of birth of a child with trisomy 21 in women of fertile age up to 35 years is 
7.3–7.4 per 10,000 live births and increases to 31.4–33.9 per 10,000 live births in women 
over 35 years [9]. From a clinical point of view, the importance of this condition is due to the 
high risk of complications in childbirth, which are observed in both mosaic and complete 
chromosomal abnormalities. The most common complications include fetoplacental insuf-
ficiency, antenatal developmental delay, and fetal death [10; 11]. Usually, aneuploidy is sus-
pected in the fetus during prenatal ultrasound examination. If a pregnant woman has a high 
risk for chromosomal abnormalities in the fetus (individual risk of 1/100 or higher) in the 
first trimester of pregnancy and/or if congenital abnormalities (malformations) are detected 
in the fetus in the first, II and III trimesters of pregnancy, the obstetrician-gynecologist di-
rects her to the medical genetics center for counseling and establishing or confirming the 
prenatal diagnosis using invasive methods of examination [12; 13]. The decision to termi-
nate pregnancy among women who received a positive diagnosis of fetal aneuploidy during 
the prenatal period varies between 86 % and 97 % [13]. Moreover, a common outcome of 
pregnancy is miscarriage, with most studies reporting 12 % to 15 % loss among recognised 
pregnancies by 20 weeks of gestation, and there is no possibility of karyotyping [14]. It ne-
cessitates the identification of morphological markers of aneuploidy in the placenta.
The purpose of investigation was to study the features of human placenta angiogen-
esis in karyotyped trisomies 21, 18, and 13.
Research problem
1) Study the morphological features of the placenta in trisomy 21, 18 and 13.
2) Evaluate the results of immunohistochemical reactions using bFGF, CD31, and 
FasL antibodies in placentas in both karyotyped trisomies 21, 18, and 13, and 
without aneuploidy.
3) Evaluate the relationship between the degree of expression of bFGF, CD31, and 
FasL and the presence of trisomies 21, 18, and 13.
Material and methods
According to the data of the St. Petersburg Medical Genetics Diagnostic Center, the 
number of pathological karyotypes detected before 22 weeks of pregnancy in St. Peters-
burg in 2017 amounted to 153 cases (table 1).
The study included 50  placentas for miscarriages at 19–20  weeks gestation, which 
made up four groups:
group 1 — 10 placentas obtained as a result of induced abortions due to karyotyped 
trisomy 21 in the fetus;
group 2 — 10 placentas obtained as a result of induced abortions due to karyotyped 
trisomy 18 in the fetus;
group 3 — 10 placentas obtained as a result of induced abortions due to karyotyped 
trisomy 13 in the fetus;
group 4 (control group) — 20 placentas obtained as a result of spontaneous miscar-
riages without any congenital defects and abnormal karyotype of the fetuses.
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Table 1. Trisomies detected in St. Petersburg in 2017 after invasive prenatal diagnosis 
before 22 weeks of pregnancy
Trisomy n %
Trisomy 21 99 64.7
Trisomy 18 37 24.2
Trisomy 13 13 8.5
Other trisomies 4 2.6
Summary 153 100
Study of the histological structure of the placenta was carried out with a standard 
method.
Immunohistochemical (IHC) reactions were performed in the Laboratory of Patho-
morphology (chief — Karev V. E.) of the Pediatric Research and Clinical Center for Infec-
tious Diseases.
IHC using monoclonal mouse antibodies bFGF (Santa Cruz Biotechnology, 1:50), 
CD31 (Dako, 1:100), FasL (Diagnostic BioSystems, 1:75) was performed in accordance 
with the manufacturer’s recommendations contained in the Protocol provided in the ac-
companying documents for the reagents.
A semi-quantitative assessment of the results of the IHC was carried out using a com-
puter analysis system for microscopic images consisting of a Zeiss Axio Imager.A2 micro-
scope, an Axiocam 506 color video camera, an Intel Pentium 4-based personal computer, 
and the ImageJ program.
Statistical analysis
AtteStat (version 13.1) was used for statistical processing of the received data. In the 
case of comparing two groups, the comparison was carried out by the student’s criterion 
or the Mann-Whitney criterion. To test the null hypothesis about the independence of the 
distribution of discrete features, the χ2 criterion was used. To test the null hypothesis of 
equality of fractions, we used the procedure of comparing fractions with approximation 
by χ2 statistics. The null hypotheses of the tests were rejected if the probability of error of 
the first kind was less than 0.05.
Results
Morphological study of the material of groups with trisomies revealed a violation 
of branching of the villi with a predominance of immature intermediate villi (Fig. 1). In 
placentas with trisomy 21, the villi were hypovascularized, and increased fibroblast prolif-
eration was detected in the stroma (Fig. 1A).
In placental villi with trisomy 13, there were pronounced hydropic changes with 
hypovascularization (Fig.  1C). At the same time, in the placenta of the control group, 
branching and vascularization of the villi were not disturbed (Fig. 1D).
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Fig. 1. Morphological features of placentas: A — placenta with trisomy 21; 
B — placenta with trisomy 18; C — placenta with trisomy 13; D — placenta of 
control group; H&E, magnification × 100
Fig. 2. Expression of bFGF in placenta’s cells: A — placenta with trisomy 21; 
B — placenta with trisomy 18; C — placenta with trisomy 13; D — placenta of con-
trol group; immunohistochemical study, magnification × 400
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Fig. 3. Expression of CD31 in placenta’s cells: A — placenta with trisomy 
21; B — placenta with trisomy 18; C — placenta with trisomy 13; D — placenta 
of control group; immunohistochemical study, magnification × 400
Fig. 4. Expression of FasL in placenta’s cells: A — placenta with trisomy 
21; B — placenta with trisomy 18; C — placenta with trisomy 13; D — placenta 
of control group; immunohistochemical study, magnification × 400
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In the immunohistochemical study of placentas, bFGF expression was observed in 
villus stroma cells — fibroblasts and macrophages, as well as in endotheliocytes (Fig. 2). 
The expression of CD31 was detected in endothelial cells of vessels of the villi (Fig. 3). 
FasL expression was present primarily in syncytiotrophoblasts and endotheliocytes 
(Fig. 4).
Summary results for the relative expression area of signal molecules are shown in 
Figure 5.
There was a statistically significant increase in bFGF expression in placentas with 
trisomy 21  — the relative area of bFGF expression in placentas of the first group was 
11.27 ± 1.75 %, and in placentas of the control group — 3.28 ± 0.26 % (p < 0.01). The rela-
tive area of CD31 expression in placentas of the first group was significantly lower than in 
the control group: 1.52 ± 0.54 % and 6.80 ± 1.54 %, respectively (p < 0.05). A similar pattern 
was observed when comparing data on the relative area of FasL expression: in placen-
tas with trisomy 21, it was statistically significantly lower than in the control group and 
amounted to 1.22 ± 0.77 % and 4.43 ± 0.79 %, respectively (p < 0.05) (Fig. 5).
In trisomy 18, there was a statistically significant increase in FasL expression in 
placentas: the relative area of FasL expression in placentas of the second group was 
11.74 ± 0.09 %, and in placentas of the control group — 4.43 ± 0.79 % (p < 0.01) (Fig. 5).
Fig. 5. Relative expression area (%) of signal molecules as a percentage of the studied groups
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In placentas with trisomy 13, the relative expression area of CD31 and FasL was sig-
nificantly lower than in the control group. Thus, the relative expression area of CD31 in 
placentas with trisomy 13 was 2.7 ± 0.84 %, in the control group — 6.80 ± 1.54 % (p < 0.05), 
and the relative expression area of FasL  — 0.16 ± 0.08 % and 4.43 ± 0.79 %, respectively 
(p < 0.01) (Fig. 5).
Discussion
In the course of our study, we found a violation of branching and hypovasculariza-
tion of villi with increased proliferation of fibroblasts in placentas of fetuses with trisomy 
21 [15]. These data correlate with the results of the Doppler metric performed in the study 
by E. Corry et al. (2016), where there was a reduction of the vascular bed and impaired 
perfusion in the placenta in trisomy 21 [3].
Increased apoptosis was observed in the material with karyotyped trisomy of chro-
mosome 18. In placentas with karyotyped trisomy 13, hydropic changes in the villus stro-
ma and angiogenesis inhibition were observed.
As a result of this work, we can say that we have studied data on the immunohisto-
chemical features of the human placenta in aneuploidy — trisomies 21, 18 and 13.
Conclusion
The features of the morphogenesis of the placenta with aneuploidy suggest this pa-
thology in cases if karyotyping is impossible.
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